OR-GUROBI-OPTIMIZATION
Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the release of Gurobi Optimizer 10.0. This release provides customers with a boost to its already industry-leading speed, the ability to embed machine learning models directly into Gurobi optimization models, and new tools for model development, monitoring, and advanced diagnosis—so users can solve new types of problems, even faster than before.
Performance Improvements and Advanced Solving Techniques
The Gurobi R&D team continues to push the boundaries of performance—resulting in improvements to existing algorithms and the development of several brand-new techniques. As a result, Gurobi Optimizer 10.0 has achieved the following performance improvements since the release of Gurobi Optimizer 9.5:
Type |
Algorithm |
Overall speed-up |
On >100sec models |
LP |
Concurrent |
10% |
25% |
Primal Simplex |
3% |
10% |
|
Dual Simplex |
3% |
10% |
|
MIP |
MILP |
13% |
24% |
Convex MIQP |
57% |
2.4x* |
|
Convex MIQCP |
28% |
88%* |
|
Non-Convex MIQCP |
51% |
2.6x |
|
*MIQP and MIQCP hard model test sets are smaller than for other problem classes. |
|||
“We’ve achieved a more than 75x speedup on MILP since version 1.1. But more importantly, Gurobi 10.0 can now solve even more models easily, including some models that were, until now, intractable,” explained Dr. Tobias Achterberg, Vice President of Research and Development at Gurobi Optimization.
Gurobi 10.0 also includes the following advances in the underlying algorithmic framework:
- New network simplex algorithm – Greatly speeds up solving LPs with network structure.
- New heuristic for QUBO models, which can arise in quantum optimization – Improves Gurobi's ability to quickly find good feasible solutions for quadratic unconstrained Boolean optimization problems.
- Significant performance gains on MIPs that contain machine learning models – Results in a more than 10x improvement on certain models that contain embedded neural networks with ReLU activation functions.
- New optimization-based bound tightening (OBBT) algorithm – Greatly speeds up solving nonconvex MIQCP models.
- Reorganized concurrent LP solver – Improves performance and reduces memory footprint.
Innovative Data Science Integration
With Gurobi Machine Learning—an open-source Python project to embed trained machine learning models directly into Gurobi—data scientists can more easily tap into the power of mathematical optimization.
Specifically, Gurobi Machine Learning allows users to add a trained machine learning model as a constraint to a Gurobi model (e.g., from scikit-learn, TensorFlow/Keras, or PyTorch). Thus, users can estimate a real-world system by training a machine learning model, and then use this machine learning model as a constraint in Gurobi, in order to optimize controls on that system.
“We’re aiming to connect the world of data science with the world of optimization. With Gurobi, you can take your machine learning ‘black box’ that’s generating your predictions and plug it directly into your optimization model—enabling you to connect your forecasting with optimization,” explained Achterberg.
With this release, we're also making it more convenient to integrate gurobipy model building with pandas objects through a new, dedicated open-source package. (Available on GitHub/PyPI in Q4 2022.)
Enterprise Development and Deployment Experience
To make its solver even more accessible and easy to use, the Gurobi team has integrated new tools for model development, monitoring, and advanced diagnosis:
- Significant enhancements to the matrix-friendly API in gurobipy – All matrix-friendly modeling objects now support multiple dimensions, and dimension handling leans consistently on NumPy, including broadcasting.
- New logistic general constraint – Makes it easy to incorporate a constraint in MIP that models the logistic function.
- NuGet package for .NET – Allows .NET users to download Gurobi directly from the NuGet server.
- Memory limit parameter that allows graceful exit – Users can set a memory limit and still get the best solution and resume the optimization after the limit was hit.
- New Compute Server dashboards – The Gurobi Compute Server now includes two new dashboards, enabling users to monitor metrics over time and drill down to the actual activity to better understand the cluster usage and application behavior.
- Expanded platform support – Gurobi 10.0 includes support for Python 3.11 and Linux on ARM 64-bit.
Gurobi introduced its Web License Service (WLS) for Docker and Kubernetes container environments last year, with the release of Gurobi 9.5. With Gurobi 10.0, the team has expanded WLS to support nearly all types of containerized environments. Moreover, customers can now also obtain WLS licenses that allow them to run Gurobi in virtually all deployment scenarios, including containerized environments, virtual machines, and bare-metal machines, across Linux, macOS, and Windows.
“Our customers love our WLS and the flexibility it provides. And now they can dynamically deploy Gurobi software in even more environments,” explained Duke Perrucci, Gurobi’s Chief Operating Officer.
Additionally, starting with Gurobi 10.0, major product releases—and their subsequent minor and technical product releases—will be supported for a term of three years from the initial major product release date. For example, Gurobi version 10.0.0 (released in November 2022) and minor releases between 10.0 and 11.0 will be supported until November 2025.
“This helps create predictability for our customers, so they know exactly how long a version will be supported,” explained Dr. Sonja Mars, Director of Optimization Support at Gurobi Optimization. “We aim to deliver expert technical guidance and support for our customers—and this policy helps eliminate the guesswork. We want our customers to get the help they need, when they need it.”
Dr. Edward Rothberg, Chief Executive Officer and Co-founder of Gurobi Optimization added, “We have the absolute best minds in optimization here at Gurobi. Across every department, you’ll find people who aren’t just smart—they’re also deeply committed to our customers and to providing the best possible experience. I’m proud to be a part of this team.”
To learn more about Gurobi 10.0, please visit gurobi.com/whats-new-gurobi-10-0/.
About Gurobi Optimization
With Gurobi’s decision intelligence technology, you can make optimal business decisions in seconds. From workforce scheduling, portfolio management, and marketing optimization, to supply chain design, and everything in between, Gurobi identifies your optimal solution, out of trillions of possibilities.
As the leader in decision intelligence, Gurobi delivers easy-to-integrate, full-featured software and best-in-class support, with an industry-leading 98% customer satisfaction rating.
Founded in 2008, Gurobi has operations across the Americas, Europe, and Asia. Over 2,500 global customers across 40+ industries run on Gurobi, including SAP, Air France, and the National Football League, as well as half of the Fortune 10 and 70% of top global tech companies. For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005243/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
